Related Experiment Videos
A simple biological way to screen dopaminergic agonists
1Laboratorio de Biociencias, Universidade Federal Fluminense, Niteroi, RJ, Brazil.
Metabolic Brain Disease
|December 1, 1992
Summary
Dopamine D1 and D2 agonists modulate retinal spreading depression velocity in vitro. This model screens dopaminergic drugs, showing D1 agonists increase and D2 agonists decrease propagation speed.
Area of Science:
- Neuroscience
- Ophthalmology
- Pharmacology
Background:
- Spreading depression in the retina is a key phenomenon sensitive to ionic changes and drug interventions.
- Dopaminergic pathways play a role in retinal function, influencing neuronal activity.
Purpose of the Study:
- To investigate the effects of dopamine D1 and D2 receptor agonists on the velocity of in vitro retinal spreading depression.
- To establish a drug screening assay for dopaminergic agents based on their impact on retinal spreading depression.
Main Methods:
- Utilized an in vitro retinal model to measure the velocity of spreading depression.
- Administered specific concentrations of D1 agonist (SKF 38393) and D2 agonist (Quinpirole).
- Tested the effects of specific antagonists (SCH23390 for D1, 1-sulpiride for D2) to confirm receptor specificity.
Main Results:
- 10 microM SKF 38393 (D1 agonist) significantly increased the velocity of spreading depression.
- 10 microM Quinpirole (D2 agonist) significantly decreased the velocity of spreading depression.
- The observed changes induced by agonists were effectively blocked by their respective antagonists.
Conclusions:
- The velocity of retinal spreading depression is modulated by dopaminergic receptor activity.
- This in vitro assay provides a physiological screen for dopaminergic drugs, identifying D1 or D2 receptor preference.
- The model offers a valuable tool for preliminary assessment of potential dopaminergic therapeutics for retinal conditions.